本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重庆莱美药业股份有限公司 第五届监事会第四十次会议决议公告 重庆莱美药业股份有限公司（以下简称"公司"）监事会于 2025 年 8 月 22 日以通讯方式向全体监事发出会议通知。本次会议于 2025 年 8 月 27 日以 通讯表决的方式召开。本次会议应出席会议监事 3 名，实际出席会议监事 3 名。本次会议的召集、召开符合《中华人民共和国公司法》《公司章程》及相关 法律法规的规定。本次会议由公司监事会主席袁媛女士召集并主持。经出席会 议监事审议和逐项书面表决，形成了以下决议： 证券代码：300006 证券简称：莱美药业 公告编号：2025-042 一、审议通过了《关于修订<公司章程>及相关制度的议案》 二、备查文件 1、第五届监事会第四十次会议决议。 特此公告。 重庆莱美药业股份有限公司 监事会 2025 年 8 月 28 日 根据《中华人民共和国公司法》《上市公司章程指引》《关于新<公司法> 配套制度规则实施相关过渡期安排》等相关规定，公司拟对《公司章程》及相关 议事规则等制度进行修订，同时《监事会议事规则》 ...

Core Viewpoint - Laimei Pharmaceutical (300006) reported a significant decline in net profit for the first half of 2025, with a year-on-year decrease of 2462.45%, indicating severe financial distress and operational challenges [1]. Financial Performance Summary - Total revenue for the first half of 2025 was 377 million yuan, down 1.19% from 382 million yuan in the same period of 2024 [1]. - The net profit attributable to shareholders was -31.38 million yuan, a drastic drop from a profit of 1.33 million yuan in the previous year [1]. - The gross margin decreased to 55.63%, down 14.54% year-on-year, while the net margin fell to -7.66%, a decline of 432.76% [1]. - Total expenses (selling, administrative, and financial) amounted to 208 million yuan, accounting for 55.12% of revenue, a decrease of 13.84% year-on-year [1]. - Earnings per share were -0.03 yuan, a significant drop of 2384.62% compared to the previous year [1]. Cash Flow and Asset Management - Operating cash flow per share was -0.00 yuan, a decrease of 100.6% year-on-year, indicating severe cash flow issues [1]. - The company reported a 61.17% increase in interest-bearing liabilities, rising from 258 million yuan to 416 million yuan [1]. - The net cash flow from operating activities decreased by 100.6%, reflecting reduced cash receipts from sales and services [4]. Changes in Financial Items - Investment properties increased by 36.87% due to the expansion of rental space by a subsidiary [3]. - Long-term borrowings decreased by 39.87% as some were reclassified to current liabilities [3]. - Other current assets fell by 40.35% due to a reduction in prepaid and deductible taxes [3]. Operational Insights - The company’s business model relies heavily on marketing, necessitating a thorough examination of the underlying drivers of this approach [7]. - Historical data indicates a median Return on Invested Capital (ROIC) of -2.04% over the past decade, with a particularly poor performance in 2020 at -10.1% [6]. Recommendations - Attention should be given to the company's cash flow situation, as the average operating cash flow over the past three years is only 16.94% of current liabilities [8].

Group 1 - The core point of the article is that Zhongheng Group's subsidiary, Laimei Pharmaceutical, has approved a guarantee for Chongqing Laimei Longyu Pharmaceutical Co., Ltd. to secure a credit facility of 10 million RMB from Hengfeng Bank [2][3] - The board and supervisory meetings of Laimei Pharmaceutical took place on August 20, 2025, where the guarantee proposal was reviewed and approved [2] - The loan term for the credit facility is set for one year [2]

每经头条（nbdtoutiao）——核心产品净值仅剩7毛钱，昔日"公募一哥"任泽松怎么了？牛市踏空真相曝 光 （记者 张明双） 截至发稿，莱美药业市值为52亿元。 每经AI快讯，莱美药业（SZ 300006，收盘价：4.96元）8月21日晚间发布公告称，公司第五届第四十五 次董事会会议于2025年8月20日以现场会议与通讯表决相结合的方式召开。会议审议了《关于<2025年 半年度报告>及其摘要的议案》等文件。 2024年1至12月份，莱美药业的营业收入构成为：医药制造占比84.09%，医药流通行业占比13.06%，其 他业务占比1.64%，服务收入占比1.21%。 ...

Core Viewpoint - Laimei Pharmaceutical reported a decline in revenue and a net loss for the first half of 2025, indicating potential challenges in its financial performance [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 377 million yuan, representing a year-on-year decrease of 1.19% [2] - The net profit attributable to shareholders was a loss of approximately 31.38 million yuan [2] - The basic earnings per share showed a loss of 0.0297 yuan [2]

Group 1 - The company is building a three-dimensional research and innovation system focusing on short, medium, and long-term goals, actively introducing quality projects and innovative technologies in the short to medium term [1] - The technology center continues to conduct research on new drug imitation and innovation, enhancing the company's product portfolio and competitiveness in specific fields [1] - The company is advancing the development of innovative technologies and products such as nano carbon iron in the long term, and is promoting the independent research and development of cell immunotherapy and personalized innovative medical technologies by its affiliate [1] Group 2 - In the reporting period, the company obtained approvals or supplementary application approvals for various products, including Clindamycin Phosphate Injection and Naloxone Hydrochloride Injection, and passed consistency evaluations [1] - The company’s product Esomeprazole Magnesium Enteric-coated Capsules and others were selected for provincial centralized procurement projects, enhancing market share [1] - Laimei Pharmaceutical reported a revenue of 377 million yuan for the first half of 2025, focusing on consolidating the leading position of its flagship product, Kanalin, in its niche market [2]

Group 1 - The core point of the article is that Laimei Pharmaceutical announced the approval of multiple proposals during the 39th meeting of its fifth supervisory board [2] Group 2 - The announcement includes the approval of the agenda and its summary [2]

证券日报网讯 8月21日晚间，莱美药业发布公告称，公司第五届董事会第四十五次会议审议通过了《关 于及其摘要的议案》等多项议案。 （文章来源：证券日报） ...

格隆汇8月21日丨莱美药业(300006.SZ)公布半年度报告，公司2025年1-6月营业收入37,719.38万元，较上 年同期下降1.19%，归属于上市公司股东的净利润为-3,137.73万元，同比减少3,270.55万元，主要是去年 同期公司之全资子公司莱美医药根据与长春海悦药业股份有限公司关于购销合同纠纷案二审判决结果， 确认营业外收入3,011.33万元所致。 ...

附表1 重庆莱美药业股份有限公司2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：重庆莱美药业股份有限公司 单位：人民币万元 非经营性资金占用 资金占用方名称 占用方与上市 公司的关联关 系 上市公司核算的会计科目 2025年期初占用资金 余额 2025年1-6月占用累计 发生金额（不含利 息） 2025年1-6月占用资 金的利息（如有） 2025年1-6月偿还累计 发生金额 2025年6月30日期末占 用资金余额 占用形成原因 占用性质 控股股东、实际控制人及 其附属企业 - - 小计 - - 前控股股东、实际控 制人及其附属企业 - - 小计 - - - - - 其他关联方及其附 属企业 小计 总计 - - - - - 其它关联资金往来 资金往来方名称 往来方与上市 公司的关联关 系 上市公司核算的会计科目 2025年期初占用资金 余额 2025年1-6月占用累计 发生金额（不含利 息） 2025年1-6月占用资 金的利息（如有） 2025年1-6月偿还累计 发生金额 2025年6月30日期末占 用资金余额 往来形成原因 往来性质（经营性 往来、非经营性往 来） 控股股东、实际控制人 ...